BIO-RAD LABORATORIES -CL B (BIO.B) Stock Fundamental Analysis
NYSE:BIO.B - New York Stock Exchange, Inc. - US0905721082 - Common Stock - Currency: USD
Overall BIO.B gets a fundamental rating of 4 out of 10. We evaluated BIO.B against 55 industry peers in the Life Sciences Tools & Services industry. BIO.B has an excellent financial health rating, but there are some minor concerns on its profitability. BIO.B is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO.B was profitable.
BIO.B had a positive operating cash flow in the past year.
In multiple years BIO.B reported negative net income over the last 5 years.
In the past 5 years BIO.B always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of -22.72%, BIO.B is doing worse than 64.29% of the companies in the same industry.
BIO.B has a Return On Equity of -32.40%. This is comparable to the rest of the industry: BIO.B outperforms 42.86% of its industry peers.
BIO.B has a better Return On Invested Capital (2.71%) than 62.50% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO.B is significantly below the industry average of 13.60%.
The last Return On Invested Capital (2.71%) for BIO.B is above the 3 year average (2.69%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -32.4% | ||
| ROIC | 2.71% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
BIO.B has a better Operating Margin (12.17%) than 69.64% of its industry peers.
In the last couple of years the Operating Margin of BIO.B has remained more or less at the same level.
BIO.B's Gross Margin of 53.68% is fine compared to the rest of the industry. BIO.B outperforms 60.71% of its industry peers.
BIO.B's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.17% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so BIO.B is destroying value.
BIO.B has less shares outstanding than it did 1 year ago.
BIO.B has less shares outstanding than it did 5 years ago.
The debt/assets ratio for BIO.B is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 3.27 indicates that BIO.B is not in any danger for bankruptcy at the moment.
BIO.B has a better Altman-Z score (3.27) than 71.43% of its industry peers.
The Debt to FCF ratio of BIO.B is 3.62, which is a good value as it means it would take BIO.B, 3.62 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 3.62, BIO.B is in the better half of the industry, outperforming 73.21% of the companies in the same industry.
A Debt/Equity ratio of 0.18 indicates that BIO.B is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.18, BIO.B perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Altman-Z | 3.27 |
ROIC/WACC0.26
WACC10.29%
2.3 Liquidity
A Current Ratio of 5.99 indicates that BIO.B has no problem at all paying its short term obligations.
BIO.B has a better Current ratio (5.99) than 80.36% of its industry peers.
BIO.B has a Quick Ratio of 4.43. This indicates that BIO.B is financially healthy and has no problem in meeting its short term obligations.
BIO.B has a better Quick ratio (4.43) than 71.43% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 |
3. Growth
3.1 Past
The earnings per share for BIO.B have decreased by -1.49% in the last year.
Measured over the past 5 years, BIO.B shows a small growth in Earnings Per Share. The EPS has been growing by 7.84% on average per year.
The Revenue has decreased by -2.46% in the past year.
Measured over the past years, BIO.B shows a small growth in Revenue. The Revenue has been growing by 2.11% on average per year.
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
3.2 Future
BIO.B is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 2.98% yearly.
Based on estimates for the next years, BIO.B will show a small growth in Revenue. The Revenue will grow by 3.30% on average per year.
EPS Next Y-15.61%
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
EPS Next 5Y2.98%
Revenue Next Year-2.11%
Revenue Next 2Y0.75%
Revenue Next 3Y1.75%
Revenue Next 5Y3.3%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIO.B is valuated rather expensively with a Price/Earnings ratio of 23.68.
Based on the Price/Earnings ratio, BIO.B is valued a bit cheaper than 71.43% of the companies in the same industry.
BIO.B is valuated at similar levels of the S&P average when we compare the Price/Earnings ratio to 27.45, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 25.79, BIO.B can be considered very expensive at the moment.
64.29% of the companies in the same industry are more expensive than BIO.B, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of BIO.B to the average of the S&P500 Index (21.90), we can say BIO.B is valued inline with the index average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.68 | ||
| Fwd PE | 25.79 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, BIO.B is valued a bit cheaper than the industry average as 78.57% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.09 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)3.02
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
5. Dividend
5.1 Amount
No dividends for BIO.B!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:BIO.B (5/13/2025, 8:19:11 PM)
250.08
+15.67 (+6.68%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners84.5%
Inst Owner Change-28.85%
Ins Owners3.65%
Ins Owner ChangeN/A
Market Cap7.00B
Analysts76.36
Price Target369.39 (47.71%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.53%
Min EPS beat(2)0.1%
Max EPS beat(2)38.97%
EPS beat(4)4
Avg EPS beat(4)40.99%
Min EPS beat(4)0.1%
Max EPS beat(4)72.05%
EPS beat(8)7
Avg EPS beat(8)21.55%
EPS beat(12)8
Avg EPS beat(12)14.41%
EPS beat(16)12
Avg EPS beat(16)19.4%
Revenue beat(2)1
Avg Revenue beat(2)-0.8%
Min Revenue beat(2)-2.71%
Max Revenue beat(2)1.11%
Revenue beat(4)2
Avg Revenue beat(4)-0.33%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)2.41%
Revenue beat(8)2
Avg Revenue beat(8)-2.22%
Revenue beat(12)3
Avg Revenue beat(12)-1.99%
Revenue beat(16)6
Avg Revenue beat(16)0.12%
PT rev (1m)0%
PT rev (3m)3.36%
EPS NQ rev (1m)-28.19%
EPS NQ rev (3m)-37.62%
EPS NY rev (1m)-10.61%
EPS NY rev (3m)-11.23%
Revenue NQ rev (1m)-3.06%
Revenue NQ rev (3m)-6.25%
Revenue NY rev (1m)-1.54%
Revenue NY rev (3m)-2.37%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 23.68 | ||
| Fwd PE | 25.79 | ||
| P/S | 2.76 | ||
| P/FCF | 21.09 | ||
| P/OCF | 13.59 | ||
| P/B | 1.05 | ||
| P/tB | 1.17 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.56
EY4.22%
EPS(NY)9.7
Fwd EY3.88%
FCF(TTM)11.86
FCFY4.74%
OCF(TTM)18.4
OCFY7.36%
SpS90.72
BVpS238.46
TBVpS213.09
PEG (NY)N/A
PEG (5Y)3.02
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -22.72% | ||
| ROE | -32.4% | ||
| ROCE | 3.43% | ||
| ROIC | 2.71% | ||
| ROICexc | 3.32% | ||
| ROICexgc | 3.67% | ||
| OM | 12.17% | ||
| PM (TTM) | N/A | ||
| GM | 53.68% | ||
| FCFM | 13.07% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexcg growth 3Y8.21%
ROICexcg growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.27
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.62 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 7.21% | ||
| Interest Coverage | -6.68 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.99 | ||
| Quick Ratio | 4.43 | ||
| Altman-Z | 3.27 |
F-Score5
WACC10.29%
ROIC/WACC0.26
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.49%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%10.92%
EPS Next Y-15.61%
EPS Next 2Y-3.01%
EPS Next 3Y2.58%
EPS Next 5Y2.98%
Revenue 1Y (TTM)-2.46%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%-4.16%
Revenue Next Year-2.11%
Revenue Next 2Y0.75%
Revenue Next 3Y1.75%
Revenue Next 5Y3.3%
EBIT growth 1Y-9.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year22.43%
EBIT Next 3Y13.71%
EBIT Next 5Y14.69%
FCF growth 1Y162.31%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y112.94%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%